Grifols, S.A. (NASDAQ:GRFS – Get Free Report) shares gapped down prior to trading on Monday . The stock had previously closed at $8.73, but opened at $8.39. Grifols shares last traded at $8.49, with a volume of 91,998 shares trading hands.
Grifols Stock Down 2.7 %
The business has a 50 day simple moving average of $8.75 and a two-hundred day simple moving average of $7.74. The company has a current ratio of 1.68, a quick ratio of 0.80 and a debt-to-equity ratio of 1.06.
Grifols (NASDAQ:GRFS – Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The firm had revenue of $1.96 billion for the quarter. Equities analysts expect that Grifols, S.A. will post 0.79 earnings per share for the current fiscal year.
Institutional Trading of Grifols
Grifols Company Profile
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.
See Also
- Five stocks we like better than Grifols
- Transportation Stocks Investing
- Inflation Risk Rising, Key Trades Investors Are Making Now
- The Basics of Support and Resistance
- 3 Oil Stocks to Watch Before Earnings Come Out
- What Are Dividend Champions? How to Invest in the Champions
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.